Healthcare firm Dr Reddy's Laboratories was the top gainer on the Sensex, rising more than 2 percent on Thursday after the company launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia in the US market.
The company's ANDA for Finasteride tablets has been awarded a 180-day period of marketing exclusivity in the US on January 2.
"The Propecia tablets has US sales of approximately USD 136 million MAT for the most recent 12 months ending October 2012, according to IMS Health," the company said in a release.
At 10:36 hours IST, the stock gained 2.13 percent to Rs 1,877 on the Bombay Stock Exchange.
Dr Reddys Labs stock price
On November 24, 2015, Dr Reddys Laboratories closed at Rs 3388.60, down Rs 12.35, or 0.36 percent. The 52-week high of the share was Rs 4382.95 and the 52-week low was Rs 3010.00.
The company's trailing 12-month (TTM) EPS was at Rs 103.55 per share as per the quarter ended September 2015. The stock's price-to-earnings (P/E) ratio was 32.72. The latest book value of the company is Rs 623.38 per share. At current value, the price-to-book value of the company is 5.44.
READ MORE ON Dr Reddy's Laboratories
Set email alert for
ADS BY GOOGLE
video of the day
Nifty to fall below 7500 if Q3 disappoints; GST key: Kumar